Releases

Media coverage

Newsletter

Subscribe to our newsletter

Archive


Jan 21, 2016
In December, new and existing shareholders subscribed for shares in Lytix Biopharma for approximately 80 million NOK. 

'We managed to successfully raise the money we needed, but it was challenging', says Unni Hjelmaas, CEO. Investments in new biotech companies fell by almost 20 percent last year.

Read article in Dagens Næringsliv (only in Norwegian)